RxDoctor Payments Data

Robert Harbour, MD

Ophthalmology · Pensacola, FLNPI 1174519185

Payments from drug & device makers

$1,901in general payments, 2019–2025

Across 74 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$210
  • Alcon$191
  • Bausch & Lomb Americas Inc.$182
  • Sun Pharmaceutical Industries Inc.$90
  • Glaukos Corporation$80
  • plus $146 from 5 others

What the payments were for

  • Food & beverage$1,901100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,901 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$348,549
Medicare patients
994
Services billed
3,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost123$68,549
RestasisCyclosporine49$53,132
RhopressaNetarsudil Mesylate58$33,758
Prednisolone Acetate364$18,190
CombiganBrimonidine Tartrate/Timolol41$16,359
Brimonidine Tartrate261$14,951
Latanoprost782$14,519
Alphagan PBrimonidine Tartrate22$12,425
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol69$10,822
Timolol Maleate705$8,315
RocklatanNetarsudil Mesylat/Latanoprost19$6,216
Travoprost29$6,121
Cyclosporine11$4,356
SimbrinzaBrinzolamide/Brimonidine Tart17$4,243
Fluorometholone45$3,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,002$150,465235 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$34$39,97477 claims
AlconSimbrinza$191$4,24317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →